Evidence map›Paper›PMID 34619287›Full record

ReviewAdvanced drug delivery reviews2021

Delivering more for less: nanosized, minimal-carrier and pharmacoactive drug delivery systems.

Emma L Etter, Kuo-Ching Mei, Juliane Nguyen

Open access · greenAbstract readReview
In one paragraph

Review in Advanced drug delivery reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 87 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. The Carbon Dots from Seabuckthorn (Journal of functional biomaterials · 2025
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Emma L EtterDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Kuo-Ching MeiDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Juliane NguyenDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: julianen@email.unc.edu.
University of North Carolina at Chapel Hill · US

Funding

Polarizing Macrophages to Tumor Suppressors by Blocking Multiple CCR2 Chemokine Receptor EpitopesR01CA241679 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NGUYEN, JULIANE · 2020 to 2024
$1.9M
RNA EXO-Codes: A novel way to reprogram pathological exosomesR01EB023262 · NIBIB · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NGUYEN, JULIANE · 2017 to 2020
$1.7M
Antibody Fragments as Biochemical Tools to Interrogate CD9 Function in Inflammatory DiseasesR21GM135853 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NGUYEN, JULIANE, WOHLFERT, ELIZABETH · 2020 to 2021
$433k
NCI NIH HHS R01 CA241679NIBIB NIH HHS R01 EB023262NIGMS NIH HHS R21 GM135853
6 · The paper itself

Abstract

Traditional nanoparticle carriers such as liposomes, micelles, and polymeric vehicles improve drug delivery by protecting, stabilizing, and increasing the circulatory half-life of the encapsulated drugs. However, traditional drug delivery systems frequently suffer from poor drug loading and require an excess of carrier materials. This carrier material excess poses an additional systemic burden through accumulation, if not degradable the need for metabolism, and potential toxicity. To address these shortcomings, minimal-carrier nanoparticle systems and pharmacoactive carrier materials have been developed. Both solutions provide drug delivery systems in which the majority of the nanoparticle is pharmacologically active. While minimal-carrier and pharmacoactive drug delivery systems can improve drug loading, they can also suffer from poor stability. Here, we review minimal-carrier and pharmacoactive delivery systems, discuss ongoing challenges and outline opportunities to translate minimal-carrier and pharmacoactive drug delivery systems into the clinic.

Indexed as

DNADrug CarriersDrug StabilityHumansNanoparticle Drug Delivery SystemParticle SizeProdrugsProteinsRNADNADrug CarriersNanoparticle Drug Delivery SystemProdrugsProteinsRNABioactive materialsCancerCarrier-freeDrug self-deliveryNucleic acidsPharmacokineticsProtein nanoparticle

Identifiers

PMID34619287
PMCPMC9633093
OpenAlexW3201778902

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.